Basically the success of treatment in black skin cancer can be monitored through the number of circulating tumor cells in the blood.
Both in adjuvant as well as in neoadjuvant therapy, maintrac® can help to monitor breast cancer therapy and make an optimization if required.
With maintrac® the effectiveness of chemotherapeutic agents can already be tested prior to the colon cancer treatment.
maintrac® is able to support the control of therapy success and helps choosing promising therapy strategies regarding the stage of disease and treatment.
With the possibility of testing various substances with maintrac®, the patient already gets to know the substance most likely to be effective against the CETCs even before starting chemotherapy.
In particular in the situation of watch-and-wait in prostate cancer, maintrac® can be applied for active surveillance.
After cancer therapy is successfully accomplished, the calculated course of cell counts of maintrac® can be an indication wheter stomach cancer stays in remission or is about to return.
maintrac® can also be applied for further tumor types, such as sarcoma, to monitor the therapy and/or characterize the therapy-relevant properties.
Through the accompanying determination of cell counts with maintrac®, it is possible to optimize and personalize the treatment during the whole course of disease.
With maintrac® it is possible to identify the drug which is likely to be most effective prior to the therapy.
Certain substances (targeted tumor therapies) only prove useful if tumor cells exhibit the relevant properties.
An increase of circulating tumor cells (CETC / CTC) in the blood can be determined with maintrac® and may indicate new tumor activity.
In neoadjuvant therapy, maintrac® can assess the effectiveness of treatment and draw attention to relapses at an early stage.
In addition to the monitoring of therapy success, maintrac® is able to identify medications which are most probable to be effective on the circulating tumor cells in the blood.
In the metastatic situation, the maintrac® cell courses should be interpreted individually due to various possibilities of interpretation.
During hormone and maintenance therapy, maintrac® can also support the monitoring of cancer diseases as well as the decision making concering further therapies.
During the „watch and wait“ approach, maintrac® can keep a close check on tumor activity.
On this page, you can find out about how to receive the lab request form for maintrac®; you will also be provided with information on how the blood samples should be send.
You can download our current information documents here. There you will learn about the applications of maintrac®.
Obtain an overview Verschaffen Sie sich einen Überblick zu den wichtigsten Studien und Publikationen der letzten Jahre. Bei Fragen zur Literatur wenden Sie sich gerne direkt an uns.
Find out here the most recent press releases about maintrac® cancer diagnostics.
On this page we will keep you updated about upcoming events which we are participating.
Welcome to our maintrac video archive. Here we provide you with a current selection of videos to inform you in more detail about maintrac.
How can the determination of tumor cell characteristics be used to support cancer therapy? (Part 1)
maintrac Online Forum: How can maintrac® be used to support breast cancer therapy (Part 2)
maintrac Online Forum: How can maintrac® be used to support breast cancer therapy (Part 1)
maintrac® therapeutic substance testing on circulating epithelial tumor cells
maintrac Online Forum: Changes in the Number of Circulating Tumor Cells during Radiation Therapy
Circulating tumor stem cells by stemtrac® to assess tumor aggressiveness and risk of metastasis
First international maintrac online forum
maintrac - is the most sensitive method to identify circulating tumor cells.
maintrac - identifies and counts there circulating tumor cells in a bloodsample.
stemtrac®, a maintrac special test, identifies the cancer cells capable of proliferation (circulating tumor stem cells) in a blood sample.
maintrac - An increase in circulating tumor cells is highly corellated to a high risk of metastasis/recurrence.